EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Open label experience of repeated OnabotulinumtoxinA injections towards the sphenopalatine ganglion in patients with chronic cluster headache and chronic migraine

Lucy Simmonds iD, Kent Are Jamtøy, Irina Aschehoug, Sozaburo Hara, Tore W Meisingset, Manjit S Matharu iD, Erling Tronvik iD, Daniel Fossum Bratbak

Cephalalgia · 2024-08 · 44 (8)

DOI: 10.1177/03331024241273967 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cephalalgia, online erschienen am 21.08.2024. Verfasst von Lucy Simmonds und 7 weiteren Autor:innen. Beteiligte Einrichtung: Headache and Facial Pain Group, University College London Queen Square Institute of Neurology, London, UK. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Cluster Headache, Migraine Disorders. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Joint Research Unit between St. Olavs Hospital and Norwegian University of Science and Technology, NTNU Discovery, The Liaison Committee between the Central Norway Regional Health Authority and Norwegian University of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A novel technique for injection of OnabotulinumtoxinA (BTA) towards the sphenopalatine ganglion (SPG) has shown promise in refractory chronic migraine (CM) and chronic cluster headache (CCH). Open label safety and efficacy data are presented here.

Methods

Patients with refractory CM or CCH who had received at least one injection and completed headache diaries were included. Efficacy was defined as ≥50% reduction in moderate-to-severe headache days for CM, or ≥50% reduction in attack frequency for CCH, at weeks five to eight.

Results

Over 261 injections, there were 123 adverse events (AE), of which one was serious. Most (93%) AEs were mild and all were transient. The 50% response to one injection was 81% for CM and 69% for CCH. The response gradually reduced over subsequent months for CM but stayed between 55% and 67% for CCH. Repeated injections were beneficial.

Conclusions

Injections resulted in improvement for both groups and was maintained with repeated injections. Repeat injection after three months may be beneficial in CM. Adverse events were not uncommon, but universally transient, presumably as a result of the mechanism of action of BTA. Repeated BTA injection towards the SPG could be an effective treatment for refractory CM and CCH. Larger, randomised, placebo-controlled trials are required.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Botulinum Toxins, Type ACluster HeadacheMigraine DisordersHumansMaleFemaleAdultMiddle AgedTreatment OutcomeChronic DiseaseSphenopalatine Ganglion BlockGanglia, ParasympatheticAged

Stichwörter der Autor:innen

botulinum toxin type arefractory cluster headacherefractory headacherefractory migraine

Substanzen

Botulinum Toxins, Type Aonabotulinum toxin A

Autor:innen und Institutionen

  • Headache and Facial Pain Group, University College London Queen Square Institute of Neurology, London, UK.
  • Headache and Facial Pain Group, The National Hospital for Neurology and Neurosurgery, London, UK.
  • Department of Neuromedicine and Movement Science, NTNU Norwegian University of Science and Technology, Trondheim, Norway.
  • Department of Maxillofacial Surgery, St Olav's University Hospital, Trondheim, Norway.
  • Department of Neurosurgery, St Olav's University Hospital, Trondheim, Norway.
  • NorHEAD, Norwegian Headache Research Centre, Norway.

ORCID-Profile: Lucy Simmonds, Manjit S Matharu, Erling Tronvik

Förderung

  • Joint Research Unit between St. Olavs Hospital and Norwegian University of Science and Technology
  • NTNU Discovery
  • The Liaison Committee between the Central Norway Regional Health Authority and Norwegian University of Science and Technology

Zitieren

APA

Simmonds, L., Jamtøy, K. A., Aschehoug, I., Hara, S., Meisingset, T. W., Matharu, M. S., Tronvik, E., & Bratbak, D. F. (2024). Open label experience of repeated OnabotulinumtoxinA injections towards the sphenopalatine ganglion in patients with chronic cluster headache and chronic migraine. Cephalalgia, 44(8). https://doi.org/10.1177/03331024241273967

Vancouver

Simmonds L, Jamtøy KA, Aschehoug I, Hara S, Meisingset TW, Matharu MS, et al. Open label experience of repeated OnabotulinumtoxinA injections towards the sphenopalatine ganglion in patients with chronic cluster headache and chronic migraine. Cephalalgia. 2024;44(8). doi:10.1177/03331024241273967

BibTeX
@article{Simmonds2024,
  author = {Simmonds, Lucy and Jamtøy, Kent Are and Aschehoug, Irina and Hara, Sozaburo and Meisingset, Tore W and Matharu, Manjit S and Tronvik, Erling and Bratbak, Daniel Fossum},
  title = {Open label experience of repeated OnabotulinumtoxinA injections towards the sphenopalatine ganglion in patients with chronic cluster headache and chronic migraine},
  journal = {Cephalalgia},
  year = {2024},
  volume = {44},
  number = {8},
  doi = {10.1177/03331024241273967}
}
Kostenlos starten →